Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

Atrial natriuretic peptide (ANP) is elevated in patients with type-2 diabetes and microalbuminuria.

Who Took Part

According to the abstract, 2 subjects were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Eight normoalbuminuric diabetic subjects underwent a randomised single blind study of 60 min intravenous infusion of ANP or vehicle.

Seven normoalbuminuric type-2 diabetes subjects received further ANP infusions during euglycaemia and during hyperglycaemia.

How the Study Was Run

In design terms this was a randomized and single-blind study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Only one side, usually the subjects, was kept unaware of whether ANP (Atrial Natriuretic Peptide) was given.

Eight non-diabetic controls underwent ANP infusion alone.

What Was Measured

Topics PubMed links to this paper include Albuminuria, Atrial Natriuretic Factor, Cyclic GMP, Diabetes Mellitus, Type 2, Hyperglycemia, Kidney and Sodium.

What This Means in Plain Language

The paper is a randomized and single-blind study of ANP (Atrial Natriuretic Peptide) in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Irish journal of medical science), a journal based in Ireland.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.